Study of serum antibodies against three eye muscle antigens and the connective tissue antigen collagen XIII in patients with Graves' disease with and without ophthalmopathy: correlation with clinical features.

OBJECTIVE The extraocular muscles are one of the primary tissues implicated in the autoimmune-mediated inflammation of thyroid-associated ophthalmopathy (TAO). Our aim was to determine the prevalence and level of antibodies against three candidate eye muscle antigens and the orbital fibroblast membrane antigen collagen XIII, in well-characterized patient groups. STUDY DESIGN AND PATIENTS The study cohort consisted of patients with Graves' hyperthyroidism with and without ophthalmopathy, controls patients with other thyroid or other autoimmune disorders and healthy subjects. The presence of eye muscle antibodies was determined using an optimized and standardized enzyme-linked immunosorbent assay. We measured antibodies against (i) the 67-kDa flavoprotein (Fp) subunit of the mitochondrial enzyme succinate dehydrogenase; (ii) G2s, a 141 amino acid fragment of the winged-helix transcription factor FOXP1; (iii) calsequestrin, a 63-kDa calcium-binding protein; and (iv) collagen XIII, a connective tissue protein that is closely linked to the congestive ophthalmopathy subtype of TAO. Eye muscle antibody levels were correlated with clinical diagnosis and presence or not of ophthalmopathy. RESULTS Prevalences of positive antibody tests to calsequestrin (75.0%) and collagen XIII (43.8%) were significantly greater in Graves' disease (GD) patients with ophthalmopathy than in healthy subjects, whereas modest significance was demonstrated with antibodies against Fp, but not G2s. Significantly greater serum levels of antibodies against calsequestrin, G2s, and collagen XIII, but not Fp, were found in GD patients with ophthalmopathy compared to control patients without eye disease and healthy subjects. CONCLUSIONS Calsequestrin and collagen XIII antibodies are the most specific to TAO, whereas antibodies against G2s, and to a lesser extent Fp, are also markers of ophthalmopathy, but less reliable. These results are unique in that it is the first time the significance of a panel of three candidate eye muscle antibodies and a connective tissue antibody have been evaluated in the same patients with ophthalmopathy.

[1]  J. Wall,et al.  Autoimmunity against eye-muscle antigens may explain thyroid-associated ophthalmopathy , 2006, Canadian Medical Association Journal.

[2]  N. Beard,et al.  Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves’ disease , 2006, Clinical and experimental immunology.

[3]  L. Kowal,et al.  The Clinicopathologic Basis of Graves' Ophthalmopathy: A Review , 2005, European journal of ophthalmology.

[4]  G. Bellastella,et al.  Serum antibodies to collagen XIII: a further good marker of active Graves’ ophthalmopathy , 2005, Clinical Endocrinology.

[5]  G. Bellastella,et al.  Extraocular muscle antibodies and the occurrence of ophthalmopathy in Graves’ disease , 2004, Clinical endocrinology.

[6]  J. Wall,et al.  Eye muscle antibodies in Graves’ ophthalmopathy: Pathogenic or secondary epiphenomenon? , 2004, Journal of endocrinological investigation.

[7]  P. Åsman.  Ophthalmological evaluation in thyroid-associated ophthalmopathy. , 2003, Acta ophthalmologica Scandinavica.

[8]  A. Bellastella,et al.  Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves’ ophthalmopathy receiving corticosteroid therapy , 2003, Clinical endocrinology.

[9]  W. Wiersinga,et al.  TSH‐R expression and cytokine profile in orbital tissue of active vs. inactive Graves’ ophthalmopathy patients , 2003, Clinical endocrinology.

[10]  G. Kahaly,et al.  Eye muscle antibodies and subtype of thyroid-associated ophthalmopathy. , 2002, Thyroid : official journal of the American Thyroid Association.

[11]  J. D. Porter,et al.  Extraocular muscle is defined by a fundamentally distinct gene expression profile , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  C. Marcocci,et al.  Management of Graves' ophthalmopathy: reality and perspectives. , 2000, Endocrine reviews.

[13]  A. Bellastella,et al.  Cloning and characterization of the novel thyroid and eye muscle shared protein G2s: autoantibodies against G2s are closely associated with ophthalmopathy in patients with Graves' hyperthyroidism. , 2000, The Journal of clinical endocrinology and metabolism.

[14]  J. Wall,et al.  Thyroid-Associated Ophthalmopathy: Clinical Features, Pathogenesis, and Management , 2000, Critical reviews in clinical laboratory sciences.

[15]  A. Bellastella,et al.  Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism. , 1999, The Journal of clinical endocrinology and metabolism.

[16]  S. Kubota,et al.  A 63 kDa skeletal muscle protein associated with eye muscle inflammation in Graves' disease is identified as the calcium binding protein calsequestrin. , 1999, Autoimmunity.

[17]  S. Kubota,et al.  The 64-kilodalton eye muscle protein is the flavoprotein subunit of mitochondrial succinate dehydrogenase: the corresponding serum antibodies are good markers of an immune-mediated damage to the eye muscle in patients with Graves' hyperthyroidism. , 1998, The Journal of clinical endocrinology and metabolism.

[18]  Y. Inoue,et al.  Localization and clinical significance of thyrotropin receptor mRNA expression in orbital fat and eye muscle tissues from patients with thyroid-associated ophthalmopathy. , 1996, Thyroid : official journal of the American Thyroid Association.

[19]  J. Wall,et al.  The ocular muscle cell is a target of the immune system in endocrine ophthalmopathy. , 1995, International archives of allergy and immunology.

[20]  C. Gorman.  Pathogenesis of Graves' ophthalmopathy. , 1994, Thyroid : official journal of the American Thyroid Association.

[21]  L. Wartofsky,et al.  Graves' ophthalmopathy: current concepts regarding pathogenesis and management. , 1993, Endocrine reviews.

[22]  N. Bernard,et al.  Thyroid-associated ophthalmopathy--a model for the association of organ-specific autoimmune disorders. , 1991, Immunology today.

[23]  L Koornneef,et al.  Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. , 1989, The British journal of ophthalmology.

[24]  S. Werner.  Modification of the classification of the eye changes of Graves' disease: recommendations of the Ad Hoc Committee of the American Thyroid Association. , 1977, The Journal of clinical endocrinology and metabolism.